Metastatic HER2-positive breast cancers resistant to anti-HER2 therapies are enriched in somatic alterations that promote MEK/ERK signaling, including biallelic loss of NF1 and activating mutations of ERBB2 [128]. This evidence concerns the gene MAPK1 and breast cancer.